Dozens of medications are available to treat anxiety disorders, spanning several drug classes with different mechanisms, timelines, and trade-offs. The most commonly prescribed first-line options are SSRIs and SNRIs, antidepressants that also work well for anxiety over a period of weeks. But the full landscape includes fast-acting sedatives, non-addictive daily alternatives, drugs that target only the physical symptoms, and even some surprising newcomers. Choosing the right one depends on the type of anxiety, how quickly relief is needed, and what side effects a person can tolerate.
SSRIs and SNRIs as the Standard Starting Point
If you visit a doctor about persistent anxiety, an SSRI or SNRI is the most likely first prescription you will walk out with. SSRIs (selective serotonin reuptake inhibitors) include drugs like sertraline, escitalopram, and paroxetine. SNRIs (serotonin-norepinephrine reuptake inhibitors) include venlafaxine and duloxetine. In adults with generalized anxiety disorder, these two classes represent the recommended first-line treatment.1PubMed Central. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review They are also widely used for panic disorder, social anxiety disorder, and several other anxiety-related conditions.
These medications do not work on the day you take them. Most people need four to six weeks before feeling the full benefit, and the first week or two can actually bring a temporary uptick in jitteriness or nausea as the body adjusts. That lag time frustrates a lot of people, and it is one of the main reasons patients stop taking them too soon. Common side effects include weight changes, sexual dysfunction, drowsiness or insomnia, and digestive upset. Not everyone experiences these, and they often improve after the first few weeks, but they are worth knowing about upfront because they shape whether someone sticks with the medication long enough for it to work.
Benzodiazepines for Rapid Relief
Benzodiazepines are the class most people picture when they think of “anxiety medication.” Drugs like alprazolam, lorazepam, diazepam, and clonazepam act quickly, often within thirty minutes to an hour, by enhancing the activity of a calming brain chemical called GABA. They are widely used to treat anxiety, insomnia, and muscle tension, and can also control seizures.2PubMed Central. Hooked on benzodiazepines: GABAA receptor subtypes and addiction That speed and potency make them appealing for acute panic episodes or severe anxiety spikes that need to be brought under control right away.
The catch is that benzodiazepines carry real risks when used beyond the short term. They were initially thought to be relatively harmless, but research has since shown they can cause dependence, withdrawal symptoms, and cognitive impairment. Long-term use has been linked to problems with processing speed, visuospatial ability, and verbal learning. Meta-analyses found that even after stopping benzodiazepines, cognitive function improved but did not fully recover to the level seen in people who had never taken them.3PubMed. The effects of benzodiazepines on cognition There has also been concern about a link to dementia, though a recent review concluded that benzodiazepines do not appear to be a significant risk factor for dementia on their own. Still, the problems with tolerance, dependency, and adverse effects are reason enough to be cautious about long-term prescribing.4PubMed. Clearing the confounding confusion: Benzodiazepines and the risk of dementia?
In practice, many clinicians prescribe benzodiazepines as a bridge: something to take during the first few weeks while an SSRI or SNRI builds up to full effect. Using them this way keeps the exposure short and lets the patient get through the hardest early stretch of treatment. When benzodiazepines are used long-term, discontinuation requires a careful taper rather than abrupt stopping, because withdrawal can produce rebound anxiety, insomnia, and in rare cases seizures.
Buspirone as a Non-Addictive Daily Option
Buspirone occupies an unusual spot in the anxiety treatment lineup. It is the first non-benzodiazepine anxiolytic developed specifically for generalized anxiety disorder. Rather than acting on GABA receptors, buspirone works as a partial agonist at serotonin 5-HT1A receptors, giving it a completely different pharmacological profile from benzodiazepines. That different mechanism means it does not cause sedation, muscle relaxation, or the euphoria that drives misuse, and it carries a generally superior safety profile with fewer and more tolerable side effects.5The Internet Journal of Pharmacology. Buspirone And Anxiety Disorders: A Review With Pharmacological And Clinical Perspectives
The trade-off is that buspirone shares the slow onset problem of SSRIs. It takes a couple of weeks of consistent daily use before the anxiolytic effect kicks in, and it will not help during an acute panic attack. People who have previously taken benzodiazepines sometimes find buspirone disappointing because it lacks that immediate “calm wash.” But for someone who needs daily anxiety management without the risks of dependency, buspirone is a genuinely useful tool that does not get enough attention.
Beta-Blockers for the Physical Side of Anxiety
Not all anxiety is purely mental. For many people, the worst part is what happens in the body: racing heart, trembling hands, sweating, shaky voice. Beta-blockers like propranolol target exactly those physical symptoms by blocking the effects of adrenaline on the heart and muscles. Propranolol is one of the very few medications successfully used for stage fright, and it has also been studied in post-traumatic stress disorder.6PubMed Central. Propranolol versus Other Selected Drugs in the Treatment of Various Types of Anxiety or Stress, with Particular Reference to Stage Fright and Post-Traumatic Stress Disorder
Musicians and public speakers are probably the best-known users. Some performers take propranolol before going on stage to reduce the peripheral symptoms of sympathetic arousal: the shaking hands, the pounding heart, the quiver in the voice.7Quality in Sport. Beta-blockers in Musicians: Mechanisms, Clinical Evidence, Prevalence, and Ethical Parallels with Anti-Doping Regulation in Precision Sports – A Narrative Review Beta-blockers do not reduce the psychological experience of worry or dread, so they are not a standalone solution for generalized anxiety. They work best for situational anxiety where the physical symptoms are the main problem. A doctor might prescribe them on an as-needed basis rather than daily, and they are generally well tolerated at the doses used for performance anxiety.
Hydroxyzine and Other Antihistamines
Hydroxyzine is an antihistamine that has been used in anxiety treatment for decades, sometimes as a bridge or as an option for patients who cannot take other medications. It is sedating, which accounts for much of its anxiolytic effect, and it acts quickly enough to be useful for situational anxiety or as a sleep aid in anxious patients.8PubMed Central. Hydroxyzine for generalised anxiety disorder In a double-blind trial comparing hydroxyzine, buspirone, and placebo in patients with generalized anxiety disorder, hydroxyzine showed a clear advantage over placebo on the primary anxiety measure, with both hydroxyzine and buspirone outperforming placebo on secondary measures.9PubMed. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder
Hydroxyzine does not carry a risk of dependence, which gives it an advantage over benzodiazepines in patients with a history of substance misuse. The downside is sedation, dry mouth, and a general “groggy” feeling that limits its usefulness during the day. Some people find it helpful as a nighttime anxiolytic that also addresses the insomnia that often accompanies anxiety disorders.
Pregabalin and Gabapentinoids
Pregabalin is approved for generalized anxiety disorder in many countries outside the United States, where it is more commonly known as a nerve pain and seizure medication. It works by binding to a specific subunit of voltage-gated calcium channels in overexcited neurons, reducing the release of excitatory neurotransmitters like glutamate.10PubMed Central. Pregabalin for the treatment of generalized anxiety disorder: an update The result is a calming effect that sets in faster than SSRIs, often within the first week.
A meta-analysis found that pregabalin was significantly more effective than placebo for both generalized anxiety disorder and social anxiety disorder. Gabapentin, the related drug in the same class, also outperformed placebo in reducing preoperative anxiety.11PubMed Central. Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale Pregabalin can cause dizziness, drowsiness, and weight gain. There have also been growing concerns about misuse potential, particularly at high doses, so prescribers in some countries have tightened regulations around it in recent years.
When First-Line Treatment Falls Short
A frustrating reality of anxiety treatment is that the first medication tried does not always work well enough. Estimates vary, but a substantial number of patients with generalized anxiety disorder do not achieve full remission on an SSRI or SNRI alone. When that happens, clinicians sometimes add a second medication on top of the first, a strategy called augmentation.
Atypical antipsychotics such as quetiapine, risperidone, and olanzapine have been explored as add-on treatments for refractory generalized anxiety disorder. A small pilot trial suggested that quetiapine added to standard therapy might benefit patients with treatment-resistant GAD.12PubMed. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial However, randomized controlled trials of these agents have produced inconsistent results.13PubMed Central. Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders Overall, while data suggest some efficacy for augmentation with atypical antipsychotics, larger and more rigorous trials are needed before these agents can be broadly recommended.14PubMed. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder Atypical antipsychotics carry their own side effect burden, including metabolic changes, weight gain, and sedation, so they are generally reserved for cases where less risky options have been exhausted.
Combining Medication With Therapy
One of the most common questions people have is whether medication alone is enough or whether therapy should be added. The answer depends partly on the disorder and partly on the person’s age. In one large trial of children with anxiety disorders, combination therapy (sertraline plus cognitive behavioral therapy) produced an improvement rate of about 81%, compared with roughly 60% for CBT alone and 55% for sertraline alone. All three approaches beat placebo, but the combination was clearly superior to either monotherapy.15PubMed Central. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety
In adults, the picture is murkier. A trial of venlafaxine plus CBT versus venlafaxine alone in adults with generalized anxiety disorder found no added benefit from combining the two. Patients who received the combination did not score better on primary or secondary measures than those who received the medication by itself.16PubMed Central. Combined medication and cognitive therapy for generalized anxiety disorder Meanwhile, in panic disorder, adding imipramine to CBT produced stronger results during the maintenance phase, but that same combination also led to the highest relapse rate after treatment ended, suggesting that the medication may have interfered with the lasting learning effects of therapy.17JAMA. Cognitive-Behavioral Therapy, Imipramine, or Their Combination for Panic Disorder: A Randomized Controlled Trial The takeaway is not that combination is pointless but rather that more is not automatically better. The value of adding therapy to medication, or medication to therapy, depends on the specific diagnosis and the patient’s goals.
Anxiety Medication in Children and Older Adults
Treating anxiety at the extremes of age requires extra caution. In children and adolescents, SSRIs are the most commonly used first-line anti-anxiety medication, consistent with published guidelines and meta-analyses of randomized trials showing their efficacy for pediatric anxiety. Benzodiazepines are used in younger populations primarily for short-term treatment.18PubMed Central. Treating pediatric anxiety: Initial use of SSRIs and other anti-anxiety prescription medications However, adverse events deserve attention: a meta-analysis found that children and adolescents taking antidepressants reported significantly more side effects and serious adverse events compared with placebo, and were also more likely to discontinue treatment due to those effects.19JAMA Psychiatry. Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis Monitoring by a prescribing clinician is especially important in younger patients, particularly during the first weeks of treatment.
In older adults, the concern shifts toward falls, confusion, and drug interactions. The American Geriatrics Society maintains the Beers Criteria, a widely used list of potentially inappropriate medications for older adults.20PubMed Central. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults Benzodiazepines feature prominently on that list because of their association with falls, sedation, and cognitive impairment in aging brains. SSRIs are generally preferred, though even those can increase fall risk through dizziness and a rare side effect of lowered sodium levels. Buspirone and hydroxyzine tend to be better tolerated options in this age group, though hydroxyzine’s sedation still matters in someone already at risk of falling.
Tapering Off Anxiety Medications
Starting medication gets more attention than stopping it, but the process of discontinuation is where many people run into trouble. SSRIs and SNRIs can produce withdrawal symptoms including dizziness, irritability, “brain zaps” (brief electric-shock sensations in the head), and flu-like feelings. These symptoms are sometimes mistaken for a relapse of the original anxiety disorder, which can lead to people restarting medication they no longer need.
Standard guidelines have traditionally recommended short tapers of two to four weeks down to the minimum therapeutic dose before stopping. But research has shown that these short tapers offer little benefit over abrupt discontinuation and are often poorly tolerated. A more effective approach involves tapering over months and reducing the dose hyperbolically, meaning the dose cuts get progressively smaller as you approach zero. This kind of slow taper reduces the biological effect on serotonin transporters in a gradual, linear fashion and minimizes withdrawal symptoms far more effectively than a quick step-down.21PubMed. Tapering of SSRI treatment to mitigate withdrawal symptoms If you are planning to stop an anxiety medication, working with your prescriber to design a slow taper is one of the most important steps you can take.
Pharmacogenomic Testing
You may have heard about genetic tests that claim to predict which psychiatric medications will work best for you. The idea behind pharmacogenomics is real: there is considerable person-to-person variability in how people respond to anxiety medications, and some of that variability comes from genetic differences in the liver enzymes that metabolize these drugs. The two enzymes that matter most for antidepressants and anxiolytics are CYP2D6 and CYP2C19. Variants in the genes for these enzymes can make someone a rapid metabolizer (who breaks down the drug too quickly for it to work well) or a poor metabolizer (who clears it too slowly, increasing the risk of side effects).22Nature Mental Health. Clinical implementation of pre-emptive pharmacogenomics in patients with anxiety disorders
In practice, pharmacogenomic testing is still finding its footing. It is most useful for identifying people at the extremes of metabolism, the ones who will almost certainly need a higher or lower dose than standard. For the majority of people who fall somewhere in the middle of the metabolizer spectrum, the test results are less actionable. Testing is becoming more common in treatment-resistant cases where a patient has failed multiple medications, and some clinicians use it preemptively to narrow down starting choices. It is not a crystal ball, but for the right patient it can save months of trial and error.
Supplements and Over-the-Counter Options
People who are wary of prescription medication often look to supplements. A systematic review of randomized controlled trials found that about 71% of the trials reviewed showed a positive direction of evidence for herbal and nutritional supplements in treating anxiety symptoms. Reported side effects were mild to moderate. The strongest evidence pointed to supplements containing passionflower or kava extracts, as well as combinations of the amino acids L-lysine and L-arginine.23PubMed Central. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review
That said, “positive direction of evidence” is a low bar compared with what is expected of prescription drugs. Most supplement trials are small, and the manufacturing quality of over-the-counter products varies widely since they are not regulated like pharmaceuticals. Kava, while effective in some trials, has been associated with rare cases of liver toxicity, and several countries have restricted or banned its sale at various points. If you want to try a supplement, it is worth telling your doctor, partly to avoid interactions with other medications and partly because anxiety bad enough to drive you to the supplement aisle might benefit from a more proven treatment.
Emerging Treatments
The biggest new frontier in anxiety pharmacology involves psychedelic-assisted therapy and novel glutamate-targeting drugs. A review of nine independent trials testing ayahuasca, ketamine, LSD, MDMA, and psilocybin found encouraging results in reducing anxiety symptoms and improving social function in patients with generalized anxiety disorder, social anxiety disorder, and anxiety related to medical conditions.24PubMed Central. Efficacy and Safety of Psychedelics in Treating Anxiety Disorders Ketamine, which works through a completely different mechanism than traditional anxiolytics by blocking NMDA glutamate receptors, showed particular promise. In a randomized crossover trial for social anxiety disorder, a single ketamine infusion produced a significantly greater reduction in anxiety compared with placebo, with about a third of participants meeting response criteria within two weeks.25PubMed Central. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial
These are still early days. Most psychedelic-assisted trials are small, and the regulatory landscape is shifting quickly. Ketamine is already available off-label through specialty clinics, but the cost is high and insurance coverage is inconsistent. MDMA-assisted therapy ran into regulatory setbacks in 2024 when an FDA advisory committee raised concerns about the clinical trial methodology, and psilocybin has only been approved for limited therapeutic use in a handful of jurisdictions. For most people with anxiety right now, these treatments are more of a future possibility than an accessible current option.
Why Placebo Response Complicates the Picture
One wrinkle in evaluating anxiety medication that rarely comes up in patient-facing conversations is the unusually large placebo response in anxiety trials. A meta-analysis covering 135 studies and over 12,500 patients found that people randomly assigned to take a placebo pill showed a large overall improvement, with average response and remission rates in placebo groups of about 37% and 24%, respectively.26PubMed Central. Placebo response in trials with patients with anxiety, obsessive-compulsive and stress disorders across the lifespan That does not mean anxiety medications are just placebos. It means the margin a drug needs to clear to prove it works better than a sugar pill is narrower than you might expect, and it partly explains why some anxiety drug trials fail even when patients in both arms improve substantially.
The high placebo response also has a practical implication for you as a patient. The act of seeking treatment, having a structured relationship with a clinician, and believing you are doing something about your anxiety all contribute meaningfully to improvement. That context effect is real, not imaginary, and it works alongside whatever pharmacological benefit the medication itself provides. It also means that if a medication “works” for you, some of that improvement genuinely comes from the treatment relationship and from your own expectation of getting better, and that is worth preserving through good follow-up care rather than treating medication as something you take in isolation.